Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BGM vs INCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INCR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–4 Matrix Metrics)

INCR Overall Winner 6-Pillar Tally: BGM 3 – 3 INCR Matrix Metrics: BGM 4 – 5 INCR

As of Nov 20, 2026, Intercure Ltd. (INCR) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas INCR carries 66.8/100 (BUY) at $3.24 (6.2x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: INCR earns the overall head-to-head edge with a stronger Unified Composite Score (66.8/100 BUY vs. BGM 59.6/100 HOLD) and 0.07β · 80% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8); meanwhile INCR is in a Breakdown options structure phase (RSI 32.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs INCR
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
INCR NASDAQ Head-to-Head Winner
Intercure Ltd. Ordinary Shares
Pharmaceutical Preparations
$3.24
-7.16% 1D
Market Cap $45.5M
TTM Revenue $243M
Forward P/E 6.2x
Beta / 30D Vol 0.07β · 80% Vol
Unified Composite Score
66.8 / 100 BUY
Tech 68.0 Fund 62.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 32.8 · SMA20: $3.86 · SMA50: $4.60

6-Pillar Scorecard Institutional Category Breakdown (BGM 3 – 3 INCR)

Columns: Metric · BGM · INCR
1. Valuation Multiples INCR
Forward P/E N/M 6.2x
Trailing P/E N/M 6.2x
PEG Ratio N/M N/M
EV / Revenue 2.3x 0.2x
2. Growth & Scale BGM
Revenue Growth (YoY) +69.8% +23.9%
Earnings Growth (YoY) +0.0% -84.7%
TTM Revenue (USD) $48M $243M
Market Cap $108.6M $45.5M
3. Profitability & Quality INCR
Gross Margin 16.9% 16.7%
Operating Margin -23.4% 0.0%
Net Profit Margin -44.2% -13.2%
Return on Equity (ROE) -7.4% -9.3%
4. Balance Sheet & Cash Flow BGM
Cash Generation (TTM) -$9.2M EBITDA -$55M EBITDA
Cash Flow Margin -19.3% EBITDA Mgn -22.8% EBITDA Mgn
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $7.59 Book/Sh · -9.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INCR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 72.9% (<1st %ile)
Put/Call OI Skew N/A 3.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity 40.3% of Rev ($19M) 16.7% of Rev ($41M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (4) vs INCR (5)
Institutional Metric BGM INCR Criterion Row Edge
Market Capitalization
Scale
$108.6M $45.5M Larger Scale BGM
Trailing P/E Ratio
Valuation
N/M 6.2x Lower Multiple INCR
Forward P/E Ratio
Valuation
N/M 6.2x Lower Multiple INCR
Revenue Growth (YoY)
Growth
+69.8% +23.9% Higher Growth BGM
Operating Margin (TTM)
Profitability
-23.4% 0.0% Higher Margin INCR
Net Profit Margin
Profitability
-44.2% -13.2% Higher Margin INCR
Return on Equity (ROE)
Capital Efficiency
-7.4% -9.3% Higher ROE BGM
52-Week Range Position
Momentum
74% ($0–$11) 47% ($1–$6) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 0.07β · 80% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 66.8 / 100 (BUY) Higher Composite INCR
Trailing 12M Revenue (USD)
Operating Scale
$48M $243M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 16.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) -$55M EBITDA ($7.59 Book/Sh · -9.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BGM +9.87 pp
BGM: -18.37% · INCR: -28.24%
3M Horizon BGM +2360.45 pp
BGM: +2636.45% · INCR: +276.0%
6M Horizon BGM +2344.41 pp
BGM: +2674.74% · INCR: +330.33%
1Y Horizon INCR +174.33 pp
BGM: -10.66% · INCR: +163.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs INCR. Trailing 12-month operating profitability (BGM -23.4% vs INCR 0.0%) and valuation multiples (BGM N/M vs INCR 6.2x Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
INCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$243M
Gross Margin16.7%
Op. Margin0.0%
ROE / Fwd P/E-9.3% · 6.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INCR BREAKDOWN
59d in phase · OBV ACCUMULATION
Current IV 72.9%
IV Percentile <1st %ile
Put/Call OI Skew 3.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact INCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
INCR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $45.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment 16.7% of Rev ($41M)
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs INCR Key Questions & Quantitative Answers

As of Nov 20, 2026, Intercure Ltd. (INCR) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas INCR carries 66.8/100 (BUY) at $3.24 (6.2x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: INCR earns the overall head-to-head edge with a stronger Unified Composite Score (66.8/100 BUY vs. BGM 59.6/100 HOLD) and 0.07β · 80% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8); meanwhile INCR is in a Breakdown options structure phase (RSI 32.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BGM leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with INCR at +23.9% YoY revenue growth and -84.7% YoY earnings growth on $243M TTM revenue (16.7% gross margin, 0.0% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $243M for INCR. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 16.7% of Rev ($41M) (0 disclosures) for INCR.

INCR screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas INCR trades at 6.2x Forward P/E, 6.2x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-22.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus INCR (-9.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, INCR carries 72.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 3.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.07β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.